Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.75% from January 9 to January 22, 2026, lagging behind the index by approximately 0.46 percentage points [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials leading the gains at 3.14% and 2.34%, respectively. In contrast, the pharmaceutical distribution and chemical preparation sectors experienced declines of 3.26% and 2.87% [12][13]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, showing a weekly increase of 60.88%. Conversely, Luyan Pharmaceutical had the largest decline at 39.07% [13][16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry index showed a decline of 0.75%, underperforming the Shanghai and Shenzhen 300 index by 0.46 percentage points [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, while pharmaceutical distribution and chemical preparations faced declines [12]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement and usage [24]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of its drug registration certificate for a new injection, which is expected to enhance its market position [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted as a key area for future growth. Specific companies to watch include Mindray Medical, Yuyuan Medical, and others across various segments [26][28].

Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of its injectable drug, Ketorolac Tromethamine, which is a non-steroidal anti-inflammatory drug (NSAID) used for acute moderate to severe postoperative pain in adults who cannot take oral medication. This marks the company's first injectable NSAID for perioperative use, and its market launch is expected to positively impact the company's future performance [1]. Group 1 - The drug is classified as a non-steroidal anti-inflammatory analgesic and serves as an adjunct to opioid analgesics [1]. - The approval signifies a strategic expansion in the company's product offerings, particularly in the perioperative pain management segment [1]. - The introduction of this drug is anticipated to enhance the company's revenue and overall market position [1].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of a new chemical drug, Ketorolac Tromethamine Injection, which is a non-steroidal anti-inflammatory analgesic used for acute moderate to severe postoperative pain in adults who are unsuitable for oral administration [1] Group 1 - The drug Ketorolac Tromethamine Injection acts as an inhibitor of COX-1 and COX-2 enzymes [1] - It is intended to be used as an adjunct to opioid analgesics [1] - The approval signifies a potential expansion in the company's product offerings in the pain management segment [1]

Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of its injectable drug, R-ketorolac tromethamine, which is a non-steroidal anti-inflammatory analgesic used for acute moderate to severe postoperative pain in adults who cannot take oral medication [1] Group 1 - The drug R-ketorolac tromethamine acts as an inhibitor of COX-1 and COX-2 activities and is used as an adjunct to opioid analgesics [1] - The analgesic effect and safety profile of R-ketorolac tromethamine are reported to be good, significantly reducing the need for postoperative opioid medications [1] - Currently, only Nanjing Zhengke Pharmaceutical Co., Ltd. has received approval for this drug in the domestic market [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration certificate of the chemical drug Ketorolac Tromethamine Injection, marking its first non-steroidal anti-inflammatory drug (NSAID) for perioperative injection, which enhances its product pipeline in the analgesic market and is expected to positively impact future performance [1] Group 1 - The approval of Ketorolac Tromethamine Injection enriches the company's product line in the pain relief medication sector [1] - This product is expected to improve the company's market competitiveness [1] - The launch and sales of this drug are anticipated to have a positive effect on the company's future performance [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the injection of Ketorolac Tromethamine, enhancing its product pipeline and market competitiveness [1] Group 1: Product Approval - The approved product is a chemical drug, specifically an injection formulation of Ketorolac Tromethamine, with a specification of 2ml:50mg [1] - The drug is indicated for acute moderate to severe postoperative pain in adults who are unsuitable for oral administration [1] - The product has a shelf life of 24 months, with the approval valid until January 13, 2031 [1] Group 2: Market Impact - This marks the company's first non-steroidal anti-inflammatory drug (NSAID) for perioperative injection, which is expected to enrich its product line [1] - The introduction of this drug is anticipated to enhance the company's market competitiveness and overall performance [1] - However, the production and sales may be influenced by uncertain factors [1]

Core Viewpoint - The company, Enhua Pharmaceutical, has received approval from the National Medical Products Administration for the registration of its injectable drug, R-ketorolac tromethamine, which is a non-steroidal anti-inflammatory analgesic used for acute moderate to severe postoperative pain in adults who are unsuitable for oral administration [1] Group 1 - The drug R-ketorolac tromethamine is an inhibitor of COX-1 and COX-2 activities [1] - It is intended to be used as an adjunct to opioid analgesics [1] - The approval signifies a potential expansion in the company's product offerings in the pain management segment [1]